Back to company

SYNACT PHARMA ApS: Financial statements 2024

CVR: 34459975

SYNACT PHARMA ApS (CVR 34459975) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -26,274,866 and a net result of DKK -30,477,376 compared with DKK -65,408,926 the year before. Equity amounted to DKK 25,108,586. The solvency ratio was 66.4%. The company had 4 employees in the financial year.

Gross Profit
-26,274,866 kr.
Profit/Loss
-30,477,376 kr.
Equity
25,108,586 kr.
Total Assets
37,792,081 kr.
Employees
4

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2024--26.3 mio.-30.5 mio.25.1 mio.4
2023--63.4 mio.-65.4 mio.15.6 mio.3
2022--47 mio.-49.8 mio.34 mio.3
2021--43.4 mio.-41.2 mio.6.6 mio.2
2020--16.7 mio.-14 mio.11.4 mio.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

How creditworthy is SYNACT PHARMA ApS?

See the CDS score and get a full credit report with recommended credit limit and payment terms.

Read about the CDS score

Events in 2024

SYNACT PHARMA ApS: The 2023 annual report is outJun 20, 2024

SYNACT PHARMA ApS has published its annual report for 2023. Gross profit came to DKK -63,448,353, and the net result was DKK -65,408,926.

Jeppe Øvli Øvlesen joins SYNACT PHARMA ApS as adm. dir.Mar 20, 2024

As of March 20, 2024, Jeppe Øvli Øvlesen is registered as adm. dir. of SYNACT PHARMA ApS.

Torbjørn Bjerke steps down as adm. dir. of SYNACT PHARMA ApSMar 20, 2024

As of March 20, 2024, Torbjørn Bjerke has stepped down as adm. dir. of SYNACT PHARMA ApS.

About SYNACT PHARMA ApS

SYNACT PHARMA ApS is a Danish company of the type Anpartsselskab based in Holte, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named SYNACTION PHARMA ApS. The management consists of Jeppe Øvli Øvlesen, Thomas Boesen and Ann Kristin Brøgger Led. The company is owned by SynAct Pharma AB. In 2025, the company reported a gross profit of DKK -53,194,923 and a net result of DKK -59,812,937 compared with DKK -30,477,376 the year before. Equity amounted to DKK 20,295,649.